TMEM101

Across TCGA pan-cancer cohorts, TMEM101 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM101 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM101 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM101 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where TMEM101 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.680	1.000	.017	11	view →
PDAC	DFS	Median	All	0.629	0.268	.017	10	view →
GBM	OS	Tertile	All	0.771	0.416	.012	6	view →
UCEC	DFS	Median	All	1.000	0.911	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM101–CCRCC (DFS)

Open the CCRCC breakdown →